Our Rockethub pitch

Investor pitch Jan 2014

We have been featured in Democrat and Chronicle

Source: Democrat and Chronicle.com

Henrietta firm has laser focus on arthritis

Bennett J. Loudon, Staff writer5:03 a.m. EST November 28, 2013


(Photo: Staff photographer)

A local biotech startup is developing a new way to deliver gene therapy that will hopefully overcome some of the problems that have plagued the treatment approach.

Until now, it has been difficult to control where, when, and to what extent therapeutic genes could work in the body, making the treatment inefficient and, in some cases, unsafe because once a gene drug is injected, it’s constantly "on."

"The problem with gene therapy is the drug stays there for months and years, so if you want to turn it off, there is no way currently to do that," said Max Rempel, founder and president of Localized Therapeutics.

His company, which recently moved in at the High Tech Rochester business incubator in Henrietta, is developing "laser switch" technology to address those issues.

By plugging a special DNA sequence into a gene drug it can become light inducible. With the new technology, a patient with knee pain, for example, would get a shot into a joint about once a year from a doctor or nurse of the light-inducible drug. The drug would be inactive without light. The patient will get a laser wrap to place on their knee about twice a day for 10 minutes each, as needed.

The light wrap is an existing product already approved by the FDA for arthritis therapy. It’s now designed to be used alone, without drugs. The combination will stop pain and inflammation, improve lubrication and restore cartilage, said Dave Braverman, vice president of sales and marketing.

"Even if it goes somewhere else, the only place it’s going to be activated is where you shine the light," said Robin Hodownes, vice president of business development.

About 12 hours after the patient stops using the light, the drug will stop working.

Getting FDA approval, and getting a product on the market, can require 10 years and billions of dollars. But Localized Therapeutics is not planning to pursue that route. The company will license their technology to large pharmaceutical companies making the gene drugs which have the resources to see it through.

At first, Localized Therapeutics is targeting rheumatoid arthritis. Current medications only slow the progression of the disease, and many of the medications in use will lose patent protection in 2014.

It’s a potentially lucrative market. There are about 1 million people in the United States suffering from the condition, and about $23 billion is spent annually on biologic drugs.

Company officials said it will take about six years to conduct the necessary research to achieve the independent validation that is necessary before they can license the technology.



Localized Therapeutics moved in to HTR, High Tech Rochester


Four startups join HTR’s business incubator


Rochester Business Journal

November 11, 2013

High Tech Rochester Inc.’s Lennox Tech Enterprise Center in Henrietta now houses four additional startups that have joined the firm’s business incubation program.
Advis Inc., Empire Robotics Inc., Localized Therapeutics LLC and Lucidity Works LLC will be mentored in the tenets of running a business with a focus on long-term sustainability, HTR officials said.
“We work with the entrepreneurs of newly formed and emerging companies not only in evaluating a business concept but also in creating a path forward for developing their financial and business plans, manufacturing and distribution sources, go-to-market strategies and the many other long-range and day-to-day initiatives that will propel them to self-sustaining success,” said Bob Kot, HTR managing for new ventures at HTR, in a statement.
“In addition, we position them for success with funding sources and outside investors as well as with strategic partners and potential clients and customers,” Kot said.
Two of the firms were finalists in 2013 Rochester Regional Business Plan Contest. Empire Robotics earned second place, and Localized Therapeutics won third place. Each won a combination of cash and services.
(c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or email service@rbj.net.

Source: http://www.rbj.net/article.asp?aID=202575




Democrat and chronicle





I was very naive




LocalizedTherapeutics.com is developing laser-controlled gene switches for gene therapy drugs.



Graphene Devices wins business plan contest
Rochester Business Journal
Dixon Schwabl Inc. Empire Robotics Inc. won second place, and Localized Therapeutics LLC won third place. Each won a combination of cash and services.

We came to semifinals

We came to semifinals:

Eight startups reach semifinals of business plan contest

Rochester Business Journal
March 15, 2013

Eight startup companies have made the semifinals of this year’s Rochester Regional Business Plan Contest.

They are 5D Innovations, Empire Robotics Inc., Flower City Malt Lab., Graphene Devices Ltd., IMSWorkX Inc., KidsOutAndAbout.com, Localized Therapeutics LLC and Tour Builder.